Use of the CD2 signaling domain in second-generation chimeric antigen receptors
US12234274B2 · kind B2 · utility
0Cited by
32References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 5, 2021 |
| Grant date | Feb 25, 2025 |
| Priority date | — |
| Expiry date | Nov 12, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.